Clinical Trial Update: Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration [Phase 4]

View source ↗

Summary

Phase 4 safety and tolerability update of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Subfoveal Choroidal Neovascularization

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis | Conditions: Subfoveal Choroidal Neovascularization (CNV), Secondary to Age-related Macular Degeneration (AMD) | Phase 4 | Status: COMPLETED